Researchers have found in a new research that deucravacitinib significantly improves joint pain and musculoskeletal symptoms ...

From eczema and psoriasis to arthritis and Parkinson’s, the appearance of our hands can tell us a lot about the state of our ...

The Queensland institute that discovered the world’s first cervical cancer vaccine has made a breakthrough that could ...

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some ...

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

Did you know that arthritis can also affect children, and not just their joints? Juvenile arthritis is more than just joint ...

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.